Treatment of cognitive impairment in Alzheimer's disease - Wikidata - awgldk - TriplyDB

Treatment of cognitive impairment in Alzheimer's disease

Treatment of cognitive impairment in Alzheimer's disease

http://www.wikidata.org/entity/Q35236559

about

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease.Targeting Renin-Angiotensin System Against Alzheimer's Disease.

P2860

Q47724056-3A9B0B0A-F6B8-4AAA-9B34-A94956AA7BB5 Q55007046-78F4ABB2-F5CC-4681-BB3B-5215D4548CB1

P2860

Treatment of cognitive impairment in Alzheimer's disease

http://www.wikidata.org/entity/Q35236559

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Treatment of cognitive impairment in Alzheimer's disease

@ast

Treatment of cognitive impairment in Alzheimer's disease

@en

type

label

Treatment of cognitive impairment in Alzheimer's disease

@ast

Treatment of cognitive impairment in Alzheimer's disease

@en

prefLabel

Treatment of cognitive impairment in Alzheimer's disease

@ast

Treatment of cognitive impairment in Alzheimer's disease

@en

P1433

Q35236559-D2DF077E-2343-4DEB-BC20-10A7B751FD73

P1476

Q35236559-A7851A92-64AB-40C2-B124-32F48CEA682D

P2093

Q35236559-BC98891F-3E87-4EEF-9361-6F38D2612DE6

P2860

Q35236559-07EB8B93-1B0A-42FD-B0FF-F1BFB218DE28

Q35236559-0B597601-A31C-42FE-B693-43AB8421371E

Q35236559-1D326A2D-F55E-4781-BC95-87B154034A43

Q35236559-1F65C48F-BD42-42CF-AA88-03B8C61A52B1

Q35236559-20E69C1C-FAC9-45E7-BCB2-1AADB1777FB6

Q35236559-2A43402A-9D48-493C-B5DD-803296EBEA05

Q35236559-2D299F72-47DF-4C0A-B198-B12530095B4A

Q35236559-36279A5A-D42C-4EBB-BC52-6127AFCCC688

Q35236559-3C83C57F-B238-4B65-B2D7-4BDD91286E30

Q35236559-40773386-586C-4ABC-A720-6854A5C7249A

P304

Q35236559-B6ECE712-FD7D-41E8-A7AA-9EB86DA56D96

P31

Q35236559-57E74444-87CE-4FAE-A633-7C0EE691E617

P433

Q35236559-7D52BFDE-1E62-43C6-A53E-8A804E270447

P478

Q35236559-591AEE99-FCD5-4936-8797-A74CDDDDA8E0

P577

Q35236559-D76828C9-A964-4162-AB40-CEB25D79257C

P698

Q35236559-24B71417-C558-405B-A324-1CEAA5A0C37A

P921

Q35236559-82606885-AB6A-49F4-9021-1B7DA8A3C4AA

P932

Q35236559-677BECDB-6BBD-4139-8ECB-D31790F21D97

P1433

Dialogues in Clinical Neuroscience

P1476

Treatment of cognitive impairment in Alzheimer's disease

@en

P2093

Alistair Burns

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.

Vascular aspects in Alzheimer's disease.

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22034058

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3181714

http://www.w3.org/2001/XMLSchema#string